Everolimus Approved for HR-Positive Breast Cancer

被引：2
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2012年 / 2卷 / 09期
关键词：
D O I：
10.1158/2159-8290.CD-NB2016-162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：756 / 756
页数：1
相关论文
共 50 条
  • [1] Everolimus in HR-Positive Advanced Breast Cancer REPLY
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (18): : 1739 - 1740
  • [2] Real world experience with exemestane and everolimus for advanced HR-positive breast cancer.
    Wang, Ying
    Le, Dan
    Camateros, Pierre
    Lohrisch, Caroline A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Ribociclib for HR-Positive, Advanced Breast Cancer
    De Gramont, Armand
    Herrera, Alain
    de Gramont, Aimery
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 288 - 289
  • [4] Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer
    Pronzato, Paolo
    FUTURE ONCOLOGY, 2017, 13 (16) : 1371 - 1384
  • [5] Ribociclib for HR-Positive, Advanced Breast Cancer REPLY
    Hortobagyi, Gabriel N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 289 - 289
  • [6] Preclinical model of Ribociclib resistance in HR-positive breast cancer
    Aske, Jennifer Carlson
    De, Pradip
    Dey, Nandini
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negative advanced breast cancer
    Song, Xifu
    Lu, Jingjing
    Wang, Liyan
    Kong, Feifei
    Yuan, Hangyu
    Chen, Cheng
    Shan, Haixia
    JOURNAL OF BUON, 2020, 25 (05): : 2228 - 2236
  • [8] Optimizing treatment for HER2-positive HR-positive breast cancer
    Debien, Veronique
    de Azambuja, Evandro
    Piccart-Gebhart, Martine
    CANCER TREATMENT REVIEWS, 2023, 115
  • [9] Ribociclib in HR-positive, HER2-negative breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2016, 17 (11): : E482 - E482
  • [10] Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
    Lloyd, Maxwell R.
    Jhaveri, Komal
    Kalinsky, Kevin
    Bardia, Aditya
    Wander, Seth A.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (10) : 743 - 761
12345